Cibus, Inc. ( (CBUS) ) has released its Q1 earnings. Here is a breakdown of the information Cibus, Inc. presented to its investors.
Cibus, Inc. is an agricultural biotechnology company that specializes in using proprietary gene editing technologies to develop plant traits, primarily focusing on productivity and sustainability challenges in major global crops such as canola, corn, rice, soybean, and wheat. The company reported its first-quarter financial results for 2025, highlighting significant advancements in its gene editing technology and regulatory progress across various markets.
In the first quarter of 2025, Cibus made notable progress with its gene-edited herbicide tolerance traits in rice and disease resistance traits in canola. The company received positive regulatory decisions in Ecuador and the U.S., validating its RTDS technology platform. Additionally, the EU member states endorsed discussions on the regulation of plants obtained by New Genomic Techniques, marking a significant step forward for Cibus in the European market.
Financially, Cibus reported a net loss of $49.4 million for the quarter, primarily driven by a $21.0 million non-cash goodwill impairment. The company’s cash position stood at $23.6 million as of March 31, 2025, with existing resources expected to fund operations into the third quarter of 2025. Despite the financial challenges, Cibus continues to focus on expanding its trait development pipeline and commercial relationships, particularly in rice and soybean platforms.
Looking ahead, Cibus aims to achieve several milestones in 2025, including expanding commercial relationships in the Americas, advancing its soybean platform, and progressing its sustainable ingredient development projects. The company remains committed to leveraging its RTDS technology to address critical agricultural challenges and capture significant shareholder value as it approaches a pivotal point in its commercial trajectory.